BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
March 2, 2021
View Archived Issues
BioNTech initiates first-in-human study of BNT-151
Read More
First-in-human data for ACT-1004-1239
Read More
QBW-251 enters phase II for bronchiectasis
Read More
NLY-01 exerts neuroprotective effects in model of experimental autoimmune encephalomyelitis
Read More
Enrollment opens in phase II study of RO-7017773 for autism spectrum disorder
Read More
Diverse populations, long reads give genome insights
Read More
Promising interim data presented from SAD portion of MORF-057 phase I program
Read More
VBL Therapeutics initiates dosing patients in phase II study of VB-111 in rGBM
Read More
Anti-TNF-alpha antibodies presented by Sinocelltech
Read More
Bristol Myers Squibb presents new ROR-gammaT agonists
Read More
Amgen discovers kinesin-like protein KIF18A inhibitors
Read More
Alkermes patents mu-opioid receptor agonists
Read More
New Janus kinase inhibitors synthesized at Vimalan Biosciences
Read More
New bispecifics capture challenging targets
Read More
FDA clears IND application for FX-301 for postoperative pain
Read More
Alofanib shows safety and antitumor efficacy in patients with advanced gastric cancer
Read More
Myoferlin inhibitor YQ-456 shows efficacy in PDX model of colorectal cancer
Read More
FDA agrees to advance VERU-111 into phase III study in COVID-19 patients at high risk for ARDS
Read More
FDA issues complete response letter for oral paclitaxel plus encequidar in metastatic breast cancer
Read More
First patient dosed in phase II study of OTX-DED for short-term treatment of dry eye disease
Read More
Inovio reports phase III data on VGX-3100 to treat HPV-16/18 cervical HSIL
Read More
MEDI-1191 demonstrates preliminary antitumor activity in advanced solid tumors
Read More
Carna receives CTA clearance for phase I study of BTK inhibitor AS-1763
Read More
ADORA2A is a therapeutic target in progressive multiple sclerosis
Read More
Merck & Co. withdraws U.S. indication for Keytruda in metastatic SCLC after platinum chemotherapy
Read More
Hoth advances site recruitment for first-in-human study of BioLexa for atopic dermatitis
Read More
Kymera begins dosing in first-in-human study of KT-474 for atopic dermatitis or HS
Read More